Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages 733-747

  Santen, Richard J ^a   Kagan, Risa ^a,b,c   Altomare, Corrado J ^d   Komm, Barry ^d   Mirkin, Sebastian ^d   Taylor, Hugh S ^e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Sutter East Bay Medical Foundation   (United States)

^d PFIZER INC   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL ACETATE; ESTROGEN; HORMONE RECEPTOR STIMULATING AGENT; LASOFOXIFENE; OSPEMIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TISSUE SELECTIVE ESTROGEN COMPLEX; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMENORRHEA; ARM FRACTURE; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE MASS; BRAIN ISCHEMIA; BREAST CANCER; BREAST TENDERNESS; COGNITION; DEMENTIA; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPAREUNIA; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FRAGILITY FRACTURE; HEADACHE; HEART INFARCTION; HIP FRACTURE; HOT FLUSH; HUMAN; INFECTION; INSOMNIA; ISCHEMIC HEART DISEASE; LEG CRAMP; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; METABOLIC SYNDROME X; MILD COGNITIVE IMPAIRMENT; OSTEOPOROSIS; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SPINE FRACTURE; SYSTEMATIC REVIEW; TRANSDERMAL PATCH; VAGINA ATROPHY; VAGINAL DRYNESS; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; WRIST FRACTURE;

ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PROGESTINS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84895808040     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3680     Document Type: Review

References (114)

1. North American Menopause Society. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause. 2012;19:257-271.
2. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95:s1-s66.
3. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-3253. (Pubitemid 37430077)
4. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534. (Pubitemid 36951364)
5. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausalwomenwith hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712. (Pubitemid 38489892)
6. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905-931. (Pubitemid 47084672)
7. Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med. 2013;19:197-209.
8. Roman-Blas JA, Castañeda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther. 2009;11:241.
9. Komm BS, Mirkin S. Evolution of the tissue selective estrogen complex (TSEC). J Cell Physiol. 2013;228:1423-1427.
10. Carroll JS, Meyer CA, Song J, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006;38:1289-1297. (Pubitemid 44646291)
11. Wardell SE, Kazmin D, McDonnell DP. Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. Mol Endocrinol. 2012;26:1235-1248.
12. Stender JD, Kim K, Charn TH, et al. Genome-wide analysis of estrogen receptor α DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol. 2010;30:3943-3955.
13. Carroll JS, Brown M. Estrogen receptor target gene: an evolving concept. Mol Endocrinol. 2006;20:1707-1714. (Pubitemid 44148078)
14. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618-629. (Pubitemid 36210865)
15. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci. 2001;949:317-326. (Pubitemid 34059996)
16. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146:3999-4008. (Pubitemid 41175771)
17. Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, Harris HA. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol. 2008;287:40-46.
18. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology. 2009;150:1897-1903.
19. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000;141:809-820. (Pubitemid 32250507)
20. Stygar D, Muravitskaya N, Eriksson B, Eriksson H, Sahlin L. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol. 2003;1:40.
21. Carthew P, Edwards RE, Nolan BM, Tucker MJ, Smith LL. Compartmentalized uterotrophic effects of tamoxifen, toremifene, and estradiol in the ovariectomized Wistar (Han) rat. Toxicol Sci. 1999;48:197-205. (Pubitemid 29226697)
22. Berrodin TJ, Chang KC, Komm BS, Freedman LP, Nagpal S. Differential biochemical and cellular actions of premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009;23:74-85.
23. Chang KC, Wang Y, Bodine PV, Nagpal S, Komm BS. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol. 2010;118:117-124.
24. Buelke-Sam J, Cohen IR, Wierda D, Griffey KI, Fisher LF, Francis PC. The selective estrogen receptor modulator, raloxifene: a segment II/III delivery study in rats. Reprod Toxicol. 1998;12:271-288. (Pubitemid 29110890)
25. Wardell SE, Nelson ER, Chao CA, McDonnell DP. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res. 2013;19:2420-2431.
26. Lewis-Wambi JS, Kim H, Curpan R, Grigg R, Sarker MA, Jordan VC. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and downregulates estrogen receptor α and cyclin D1. Mol Pharmacol. 2011;80:610-620.
27. Bryant HU. Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation. Rev Endocr Metab Disord. 2001;2:129-138. (Pubitemid 33643899)
28. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology. 2008;149:6084-6091.
29. Ethun KF, Wood CE, Register TC, Cline JM, Appt SE, Clarkson TB. Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. Menopause. 2012;19:1242-1252.
30. Ethun KF, Wood CE, Cline JM, Register TC, Appt SE, Clarkson TB. Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model. Menopause. 2013;20:777-784.
31. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291:1610-1620. (Pubitemid 38552434)
32. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065-1079. (Pubitemid 32522600)
33. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;109:588-596. (Pubitemid 46339398)
34. Bachmann GA, Schaefers M, Uddin A, Utian WH. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. Menopause. 2009;16:877-882.
35. Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell DR Jr. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Menopause. 2008;15:94-97.
36. Buster JE, Koltun WD, Pascual ML, Day WW, Peterson C. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111:1343-1351.
37. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17β-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;110:771-779. (Pubitemid 47508739)
38. Archer DF, Pickar JH, MacAllister DC, Warren MP. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause. 2012;19:622-629.
39. Liu J, Allgood A, Derogatis LR, et al. Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2011;95:366-368.
40. Speroff L, Haney AF, Gilbert RD, Ellman H. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause. 2006;13:442-450.
41. Barbosa IC, Coutinho EM, Oladapo L, et al. An open-label study of subdermal implants of estradiol-only versus subdermal implants of estradiol plus nomegestrol acetate: effects on symptom control, lipid profile and tolerability. Gynecol Endocrinol. 2009;25:269-275.
42. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;4:CD002978.
43. Liu JH, Reape KZ, Hait HI. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2012;119:78-84.
44. Simon JA, Reape KZ, Wininger S, Hait H. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertil Steril. 2008;90:1132-1138.
45. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med. 2005;118(suppl 12B):74-78.
46. Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause. 2011;18:1172-1177.
47. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. J Bone Miner Res. 2006;21:817-828. (Pubitemid 43787988)
48. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310:1353-1368.
49. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676. (Pubitemid 34533545)
50. Farr JN, Khosla S, Miyabara Y, Miller VM, Kearns AE. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab. 2013;98:E249-E257.
51. Ziller M, Herwig J, Ziller V, Kauka A, Kostev K, Hadji P. Effects of a low-dose oral estrogen only treatment on bone mineral density and quantitative ultrasonometry in postmenopausal women. Gynecol Endocrinol. 2012;28:1002-1005.
52. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13:476-486.
53. Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103:296-305.
54. Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer. 2009;115:936-945.
55. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006;166:1027-1032.
56. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166:357-365. (Pubitemid 43244325)
57. Nichols HB, Trentham-Dietz A, Newcomb PA, et al. Postoophodoi: rectomy estrogen use and breast cancer risk. Obstet Gynecol. 2012;120:27-36.
58. Wild RA, Wu C, Curb JD, et al. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause. 2013;20:254-260.
59. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305:1305-1314.
60. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med. 2008;168:2245-2253.
61. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477. (Pubitemid 46556472)
62. Prestwood KM, Unson C, Kulldorff M, Cushman M. The effect of different doses of micronized 17β-estradiol on C-reactive protein, interleukin-6, and lipids in older women. J Gerontol A Biol Sci Med Sci. 2004;59:827-832. (Pubitemid 39167426)
63. Harman SM. Effects of oral conjugated estrogen or transdermal estradiol plus oral progesterone treatment on common carotid artery intima media thickness (CIMT), coronary artery calcium (CAC) in menopausal women: initial results from the Kronos Early Estrogen Prevention Study (KEEPS). Menopause. 2012;19:1365.
64. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med. 2012;157:104-113.
65. Hodis HN, Mack WJ. Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis [published online July 9, 2013]. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.2013.06.011.
66. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006;113:2425-2434. (Pubitemid 43948050)
67. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol. 2009;170:12-23.
68. Renoux C, Dell'aniello S, Garbe E, Suissa S. Hormone replacement therapy use and the risk of stroke. Maturitas. 2008;61:305-309.
69. Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519.
70. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336:1227-1231. (Pubitemid 351809317)
71. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost. 2010;8:979-986.
72. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004;292:1581-1587. (Pubitemid 39314964)
73. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolismamongpostmenopausalwomen:impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115:840-845. (Pubitemid 46294724)
74. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;7:CD004143.
75. Sacchini V, Zurrida S, Andreoni G, et al. Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol. 2002;9:266-271. (Pubitemid 34298631)
76. Espeland MA, Brunner RL, Hogan PE, et al. Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. J Am Geriatr Soc. 2010;58:1263-1271.
77. Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology. 2012;79:1846-1852.
78. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25:270-275.
79. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852-856.
80. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805-816.
81. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645. (Pubitemid 29384151)
82. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441-1452. (Pubitemid 41368577)
83. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas. 2000;34:65-73. (Pubitemid 30015989)
84. Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20:623-630.
85. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362:686-696.
86. Silverman SL, Chines AA, Kendler DL, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int. 2012;23:351-363.
87. Iikuni N, Hamaya E, Nihojima S, et al. Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. J Bone Miner Metab. 2012;30:674-682.
88. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of baze-doxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23:1923-1934.
89. Osphena [package insert]. Tredegar, Gwent, South Wales: Penn Pharmaceutical Services Ltd; 2013.
90. Evista [package insert]. Indianapolis, IN: Eli Lilly & Co; 2008.
91. Conbriza [summary of product characteristics]. Kent, UK: Pfizer Ltd; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product- Information/human/000913/WC500033577.pdf. Accessed November 25, 2013.
92. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23:525-535. (Pubitemid 351501893)
93. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17:480-486.
94. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry. 2005;162:683-690. (Pubitemid 40489129)
95. Jacobsen DE, Samson MM, Emmelot-Vonk MH, Verhaar HJ. Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause. 2010;17:309-314.
96. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009;92:1039-1044.
97. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16:1116-1124.
98. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17:281-289.
99. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009;92:1045-1052.
100. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92:1025-1038.
101. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92:1018-1024.
102. Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol. 2013;121:959-968.
103. Stovall DW, Utian WH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause. 2007;14:510-517.
104. Valiati B, Capp E, Edelweiss MI, de Freitas FM, Wender MC. Effect of raloxifene and low-dose percutaneous 17β-estradiol on menopause symptoms and endometrium-a randomized controlled trial. Maturitas. 2009;62:81-84.
105. Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med. 2007;52:93-96.
106. Harvey JA, Pinkerton JV, Baracat EC, Shi H, Chines AA, Mirkin S. Breast density changes in a randomized controlled trial evaluating bazedoxifene/ conjugated estrogens. Menopause. 2013;20:138-145.
107. Pickar JH, Lobo R, Ebede B, Thompson J, Mirkin S. Pooled cardiovascular safety results from phase 3 trials of bazedoxifene/conjugated estrogens. Menopause. 2012;19:1374-1375.
108. Diem S, Grady D, Quan J, et al. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Menopause. 2006;13:130-138.
109. Utian WH, Lederman SA, Williams BM, Vega RY, Koltun WD, Leonard TW. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens. Obstet Gynecol. 2004;103:245-253.
110. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000;95:726-731. (Pubitemid 30210060)
111. Arrenbrecht S, Boermans AJ. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial. Osteoporos Int. 2002;13:176-183. (Pubitemid 34241038)
112. Varas-Lorenzo C, García-Rodríguez LA, Perez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation. 2000;101:2572-2578. (Pubitemid 30350634)
113. Gorenstein C, Rennó J Jr, Vieira Filho AH, et al. Estrogen replacement therapy and cognitive functions in healthy postmenopausal women: a randomized trial. Arch Womens Ment Health. 2011;14:367-373.
114. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662. (Pubitemid 37430136)